Recent publications by HemOnc Faculty:
Christiana M. Brenin, M.D.
John J. Densmore, M.D., Ph.D.
Michael G. Douvas, M.D.
Heidi H. Gillenwater, M.D.
William W. Grosh, M.D.
Charles E. Hess, M.D.
B. Gail Macik, M.D.
Christopher Y. Thomas, M.D., Ph.D.
Geoffrey R. Weiss, M.D.
Michael E. Williams, M.D.
Twardowski PW, Brenin CM, Kies MS. Principles of Chemotherapy. In General Thoracic Surgery. (Shields, TW, LoCicero, J, and Ponn, RB, eds.) Lippincott Williams & Wilkins, Philadelphia. 2000.
Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, Densmore JJ, Williams ME, *Taylor RP. (2004) Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 172(5):3280-8.
Redfern, C.H., T.H. Guthrie, A. Bessudo, J.J. Densmore, et al. Phase II Trial of Idiotype Vaccination in Previously Treated Patients With Indolent Non-Hodgkin's Lymphoma Resulting in Durable Clinical Responses. J Clin Oncol 2006 24: 3107-3112.
Williams, M. E., J.J. Densmore, A. W. Pawluczkowycz, P.V. Beum, A.D. Kennedy, M.A. Lindorfer, S.H. Hamil, J.C. Eggleton, and R.P. Taylor. Thrice-weekly Low-dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Therapeutic Targeting in Chronic Lymphocytic Leukemia. J Immunol 2006 Nov 15;177(10):7435-43.
Douvas MG, Hogan KN, Ji Y, Bonham L, Hollenback D, Singer J, Mitchell, BS, "Effect of Lysophosphatidic Acid Acyl Transferase-Beta Inhibition in Acute Leukemias," Leukemia Research, August 2006, 30(8): 1027-1036.
Douvas MG and Monahan PE, "Life-Threatening Thrombosis Complicating the Management of Hepatic Hemorrhage: Anticoagulant Treatment in a Newborn with Hemophilia B," J Pediatr Hematol Oncol, April 2004; 26; 4: 258-263.
Gorczynski MJ, Grembecka J, Zhou Y, Kong Y, Roudaiya L, Douvas MG, Newman M, Baber G, Bielnicka I, Corpora T, Shi J, Sridharan M, Lilien R, Donald BR, Speck NA, Brown ML, Bushweller JH, "Development of an Allosteric Inhibitor of the Protein-Protein Interaction Between the Leukemia-Associated Proteins RUNX1 and CBF?," accepted for publication in Chemistry and Biology, April 2007.
POSTERS
D.K. Bol, J. Strovel, M. Douvas, P. Natarajan, Q. Zong, J. Castaneda, M. Chakiath, and B. Mitchell. "Genetic response markers for IMPDH inhibition are conserved from in vitro cell lines to ex vivo treated primary samples from leukemia patients." Poster presented at the AACR Annual Meeting, Washington, D.C., April 4, 2006.
Gillenwater HH, Tynan M, Natoli S, Schell MJ, Socinski MA. Second-Line Gemcitabine in Refractory Stage IV Non-Small Cell Lung Cancer: A Phase II Trial. Clinical Lung Cancer Vol. 2, No. 2, 133-138, 2000.
McCune JS. Hawke RL. LeCluyse EL. Gillenwater HH. Hamilton G. Ritchie J. Lindley C. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clinical Pharmacology & Therapeutics. 68(4):356-66, 2000 Oct.
Donahue A. McCune JS. Faucette S. Gillenwater HH. Kowalski RJ. Socinski MA. Lindley C. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing. Cancer Chemotherapy & Pharmacology. 47(5):373-9, 2001.
Arquette M. Wasserman T. Govindan R. Garfield D. Senzer N. Gillenwater H. Socinski M. Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation. Seminars in Radiation Oncology. 12(1 Suppl 1):59-61, 2002 Jan.
Socinski MA. Sandler AB. Israel VK. Gillenwater HH. Miller LL. Locker PK. Antonellini A. Elfring GL. Natale RB. Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma. Cancer. 95(7):1520-7, 2002 Oct 1.
Shord SS. Faucette SR. Gillenwater HH. Pescatore SL. Hawke RL. Socinski MA. Lindley C. Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Chemotherapy & Pharmacology. 51(4):328-36, 2003 Apr.
Todd Wolf, and Heidi H. Gillenwater. Treatment options for small cell lung cancer. Current Oncology Reports. 6:268-271, 2004
Gillenwater HH, Stinchcombe TE, Quaqish BF, Tyann M, Hensing TA, Socinski MA.
A Phase II trial of weekly paclitaxel and gemcitabine infused at a constant rate in patients with advanced non-small cell lung cancer. [ Clinical Trial. Clinical Trial, Phase II. Journal Article] Lung Cancer. 47(3):413-9, 2005 March.
Gillenwater HH, McCune JS, Lindley C, Steward CF, Faucette S, Zamboni WC, Kirstein MN, Shord S, Donahue A, Moore D, Socinski MA. A Phase I Trial Defining the Maximum Tolerated Systemic Exposure of Topotecan in Combination with Carboplatin and Etoposide in Extensive Stage Small Cell Lung Cancer. [Clinical Trial. Clinical Trial, Phase I. Journal Article] Cancer Investigation. 23 (6): 511-9, 2005.
Gillenwater HH, MacCallum C. Second-Line Treatment Small Cell Lung Cancer. Current Oncology Reports. 8:258-264, 2006.
Hensing TA, Hanna NH, Gillenwater HH, Gabriella Camboni M, Allievi C, Socinski MA. Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer. Anticancer Drugs. 2006 Jul; 17(6):697-704.
Stinchcombe TE, Buzkova P, Choksi J, Taylor M, Bakri K, Gillenwater H, Tynan M, Mears A, Jones PE, Socinski MA. A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer. 2006 Jun; 52(3):305-11.
Book Chapters:
Gillenwater HH and Socinski MA. Extensive Stage Small Cell Lung Cancer. In Detterbeck (ed): Diagnosis and Treatement of Lung Cancer. New York, WB Saunders Company; 2000.
Slingluff CL, Petroni GR, Yamschchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH. Clinical and Immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony stimulating factor in adjuvant or pulsed on dendritic cells. Journal of Clinical Oncology 21 (21):4016-26 (2003).
Yamschikov GC, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Teates D, Neese P, Grosh WW, Petroni G, Engelhard VH, Slingluff CL. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. International Journal of Cancer. 92(5):703-11 (2001).
Slingluff CL, Yamschchikov GV, Neese P, Galvotti H, Eastham S, Engelhard VH, Kittlesen D, Decon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz
C, Patterson JW, Conway BP, Ross WG. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Research 7(10):3012-24 (2001).
Books and Book Chapters:
BRODY'S HUMAN PHARMACOLOGY, Fourth edition; Edited by Kenneth P. Minneman, PhD; Lynn Wecker, PhD; Joseph Larner, MD, PhD; Theodore M. Brody, PhD. "Mechanisms of Action of Anti-Neoplastic Drugs."
BRODY'S HUMAN PHARMACOLOGY, Fourth edition; Edited by Kenneth P. Minneman, PhD; Lynn Wecker, PhD; Joseph Larner, MD, PhD, Theodore M. Brody, PhD. "Clinical Effects of Anti-Neoplastic Drugs."
Burns TM, Juel VC, Hess CE, Phillips LH: Motor neuron disease and serum monoclonal protein: Poor response to treatment of the paraproteinemia. J Clin Neuromusc Dis 2000; 2: 70-72
Shami, VM, Caldwell SH, Hespenheide EE, Arseneau KO, Bickston SJ, Macik BG. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared to conventional therapy. Liver Transplantation . 9:138-143, 2003.
Macik, BG. The future of anticoagulation clinics. J Thrombosis and Thrombolysis. 16:55-59. 2003.
Caldwell, SH, Chang, C, Macik BG. Recombinant Activated Factor VII(rFVIIa) as a hemostatic agent in liver disease: A break from convention in need of controlled trials. Hepatology, 39:592-598. 2004.
Malaeb BS, Gardner TA, Margulis V, Yang L, Gillenwater JY, Chung LW, Macik G, Koeneman KS. Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants. Urology 66:830-4. 2005.
Rudisill CN, Hockman RH, Degregory KA, Mutnick AH, Macik BG. Implementing guidelines for the institutional use of factor VIIa (recombinant): A multidisciplinary solution. Am J Health Syst Pharm. 63:1641-6. 2006.
Caldwell SH, Hoffman M, Lisman T, Macik BG, et al. Coagulation Disorders and Hemostasis in Liver Disease: Pathophysiology and Critical Assessment of Current Management. Hepatology Accepted with revision, June 2006
Invited Chapters and Reviews:
Macik, B.G. Coagulation point-of-care instruments. IN Blood Components and Pharmacologic Agents in the Treatment of Congenital and Acquired Bleeding Disorders, B. Alving, editor. Am Asso of Blood Banks, Bethesda, Maryland. 2000 pp15-43.
Macik, B.G. sections Platelet Disorders, Disorders of Hemostasis and Thrombosis. Medical Knowledge Self-Assessment Program 12: Eds Section editior- ME Williams, Co-editors in Chief Hatem, CJ, Kettyle WM. American College of Physicians/American Society of Internal Med, Philadelphia, PA. 2001.(Peer review)
Macik BG, Rand, JH, Konkle, BA. Thrombophilia: what's a practitioner to do? IN Hematology (Am Soc Hematol Educ Program). eds Schechter GP, Broudy VC, Williams ME. American Society of Hematology, Washington DC. 2001. pp 322-38 (Peer reviewed)
Macik, B.G. Near-Site Testing in Hemostatic Disorders. IN Consultative Hemostasis and Thrombosis. C. S. Kitchens, B.A. Alving, C. M. Kessler, eds. W. B. Saunders Company, Philadelphia, PA, 2002, pp535-547.
Chai, S and Macik, B.G. 2002. Improving the safety profile of warfarin. Sem Hematol.Vol 39:179-186. 2002.
Macik, BG- Faculty contributor hematology section. Medicine Recall, 2nd ed. Editor, JD Bergin. Lippincott Williams & Wilkins, Baltimore, MD. 2003. pp 459-511.
LoRusso K and Macik BG. Chronic Bruising and the Bleeding Diathesis Evaluation. IN Clinical Hematology. Young NS, Gerson SL, KA High, eds. Elsevier Inc. Philadelphia, PA. 2006. pp 1079-1088.
Mercer KW, Macik BG, Williams ME. Hematologic Disorders in Critically Ill Patients. Semin Respir Crit Care Med. Vol 27: 286-296, 2006.
Kubiak, K and Macik, B.G. Near-Site Testing in Hemostatic Disorders. IN Consultative Hemostasis and Thrombosis. C. S. Kitchens, B.A. Alving, C. M. Kessler, eds. W. B. Saunders Company, Philadelphia, PA, 2006, in press
Christopher Y. Thomas, M.D., Ph.D.
Thomas CY, Chouinard M, Cox M, Parsons S, Stallings-Mann M, Garcia R, Jove R, Wharen R. Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells. International J. of Cancer 104:19-27, 2003.
Loy AH, Reibel JF, Paul W Read PW, Thomas CY, Levine PA. Esthesioneuroblastoma: Continued follow-up of a single institution's experience. Arch Otolaryngol Head Neck Surg 132:134-138, 2006.
Thomas CY and Theodorescu D. The RON receptor tyrosine kinase: bystander or player in the pathogenesis of urothelial cancers? (ed) J of Urology 176:1909-1910, 2006.
Thomas CY and Theodorescu D. Chapter 28. Molecular Pathogenesis of Urothelial Cell Carcinomas and the Development of Novel Therapeutic Strategies. in Bladder Cancer: Moving the Field Forward. C. Lee and D. Wood, Eds. Humana Press 2007.
Thomas CY and Theodorescu D. Molecular Markers of Prognosis and Novel Therapeutic Strategies for Urothelial Cell Carcinomas. World J of Urology 24:565-578, 2006.
In preparation/revision:
Thomas CY, Read P, Sheng K, Bliesner D, Levine P, Reibel J. Phase I study of capecitabine combined with weekly carboplatin and intensity modulated radiation therapy for treatment of locally advanced squamous cell carcinomas of the head and neck (manuscript in preparation)
Thomas C, Stallings-Mann M, Kastan M, Chounard M, Garcia R, Jove R, Wharen R. Resistance of SKMG-3 glioblastoma cells to cell cycle arrest produced by hyperstimulation of overexpressed epidermal growth factor receptors (manuscript in revision).
Thomas C, Stallings-Mann M, Kastan M, Chounard M, Kastan M, Slack J, Parsons JT, and Robert Wharen. Inhibition of spontaneous EGFR signals suppresses cell migration but not proliferation of SKMG-3 glioblastoma cells (in preparation).
Stallings-Mann M, Wharen R, Thomas CY. Resistance of PTEN-negative glioblastoma cells to EGFR inhibitors is associated with maintenance of AKT-1 and phosphatidylinositol-3-kinase (PI3K)-dependent signaling complexes (in preparation).
Thomas C, Jameson M, Beckler A. IGF-1R signaling modulates the anti-proliferative and biochemical response of head and neck cancer cells to EGFR inhibitors (in preparation).
Hidalgo M, Villalona-Calero MA, Eckhardt SG, Grengler RL, Rodriguez G, Hammond LA, Diab SG, Weiss G, Garner AM, Campbell E, Davidson K, Louie A, O'Neil JD, von Borstel R, Von Hoff DD, Rowinsky EK. Phase I and pharmacological study of PN401 and 5-fluorouracil in patients with advanced solid malignancies. J Clin Oncol 18: 167-177, 2000.
Britten CD, Rowinsky EK, Baker SD, Weiss GR, Smith L, Stephenson J, Rothenberg M, Smetzer L, Cramer J, Collins W, Von Hoff DD, Eckhardt SG. A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT077. Clin Cancer Res 6: 42-49, 2000.
Macdonald JS, Jacobson JL, Ketchel SJ, Weiss G, Taylor S, Mills G, Kuebler JP, Rivkin S, Conrad M. A phase II trial of topotecan in esophageal carcinoma: A Southwest Oncology Group study (SWOG 9339). Invest New Drugs 18: 199-202, 2000.
Dutcher JP, Logan T, Gordon M, Sosman J, Weiss G, Margolin K, Plasse T, Mier J, Lotze M, Clark J, Atkins M. Phase II trial of interleukin-2, interferon ?, and 5-fluorouracil in metastatic renal cell carcinoma: a Cytokine Working Group study. Clin Cancer Res 6: 3442-3450, 2000.
Tolcher AW, Aylesworth C, Rizzo J, Izbicka E, Campbell E, Kuhn J, Weiss G, Von Hoff DD, Rowinsky EK. A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol 11:333-8, 2000.
Raymond E, Faivre S, Weiss G, McGill J, Davidson K, Izbicka E, Kuhn J, Allred C, Clark GM, Von Hoff DD. Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas. Clin Cancer Res 7: 1171-1180, 2001.
Tolcher AW, Eckhardt SG, Kuhn j, Hammond L, Weiss G, Rizzo J, Aylesworth C, Hidalgo M, Patnaik A, Schwartz G, Felton S, Campbell E, Rowinsky EK. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. J Clin Oncol 19: 2937-2947, 2001.
Flaherty LE, Atkins M, Sosman J, Weiss G, Clark JI, Margolin K, Dutcher J, Gordon MS, Lotze M, Mier J, Sorokin P, Fisher RI, Appel C, Du W. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: Results of two phase II Cytokine Working Group trials. J Clin Oncol 19:3194-3202, 2001.
Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001.
Hidalgo M, Aylesworth C, Hammond LA, Britten CD, Weiss G, Stephenson J Jr, Schwartz G, Patnaik A, Smith L, Molpus K, Felton S, Gupta E, Ferrante KJ, Tortora A, Sonnichsen DS, Skillings J, Rowinsky EK. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J Clin Oncol 19: 2493-2503, 2001.
Rothernberg ML, Liu PY, Wilczynski S, Hannigan EV, Weiner SA, Weiss GR, Hunter VJ, Chapman JA, Tiersten A, Kohler PC, Alberts DS. Phase II trial of oral altretamine for consolidation of complete remission in women with stage III epithelial ovarian cancer: A Southwest Oncology Group trial (SWOG-9326). Gynecol Oncol 82: 317-322, 2001.
Atkins MB, Dutcher J, Weiss G, Margolin K, Clark J, Sosman J, Logan T, Aronson F, Mier J. Kidney cancer: the Cytokine Working Group experience (1986-2001). Med Oncol 18: 197-207, 2001.
De Bono JS, Stephenson J Jr, Baker SD, Hidalgo M, Patnaik A, Hammond LA, Weiss G, Goetz A, Siu L, Simmons C, Jolivet J, Rowinsky EK. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 20: 96-109, 2002.
Villalona-Calero MA, Eckhardt SG, Weiss G, Hidalgo M, Beijnen JH, van Kesteren C, Rosing H, Campbell E, Kraynak M, Lopez-Lozaro L, Guzman C, Von Hoff DD, Jimeno J, Rowinsky EK. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res 8: 75-85, 2002.
Sondak VK, Liu P-Y, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, Thompson JA, Weiss GR, Redman BG, Jakowatz JG, Noyes RD, Flaherty LE. Adjuvant immunotherapy of resected intermediate-thickness, node negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 20: 2058-2066, 2002.
Siu LL, Rowinsky EK, Hammond LA, Weiss GR, Hidalgo M, Clark GM, Moczygemba J, Choi L, Linnartz R, Barbet NC, Sklenar IT, Capdeville R, Gan G, Porter CW, Von Hoff DD, Eckhardt SG. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with advanced solid malignancies. Clin Cancer Res 8: 2157-2166, 2002.
Margolin K, Atkins MB, Thompson JA, Ernstoff MS, Weber J, Flaherty L, Clark JI, Weiss G, Sosman J, Smith JW II, Dutcher JP, Gollob J, Longmate J, Johnson D. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 128: 214-218,2002.
Whitehead RP, Lew D, Flanigan RC, Weiss GR, Roy V, Glode ML, Dakhil SR, Crawford ED. Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a Southwest Oncology Group study. J Immunother 25:352-358,2002.
Markman M, Glass T, Smith HO, Hatch KD, Weiss GR, Taylor SA, Goodwin JW, Alberts DS. Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial. Gynecol Oncol 88:282-288, 2003.
Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan,TF, White R, Weiss GR, Redman RG, Tretter CPG, McDermott D, Smith JW, Gordon MS, Margolin KA. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A Cytokine Working Group randomized trial. J Clin Oncol 21: 3133-3140, 2003.
Weiss GR, O'Donnell MA, Loughlin K, Zonno K, Laliberte RJ, Sherman ML. A phase I study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. J Immunother 26:343-348,2003.
Peralba JM, deGraffenried L, Friedrichs W, Fulcher l, Grunwald V, Weiss G, Hidalgo M. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:28872892, 2003.
Zafar H, Takimoto CH, Weiss G. Doege-Potter syndrome: hypoglycemia associated with malignant solitary fibrous tumor. Med Oncol 20:403-408, 2003.
Edelman MJ, Chansky K, Gaspar LE, Leigh B, Weiss GR, Taylor SA, Crowley J, Livingston R, Gandara DR. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713. J Clin Oncol 22:127-132, 2004.
DeGraffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M, Freeman WA, Weiss GR. NF-?B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 15: 885-890, 2004.
Edelman MJ, Clark JI, Chansky K, Albain K, Bhoopalam N, Weiss GR, Giguere JK, Kelly K, Crowley J, Gandara DR. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 10: 5022-5026, 2004.
Hammond LA, Eckardt JR, Kuhn JG, Gerson SL, Johnson T, Smith L, Drengler RL, Campbell E, Weiss GR, Von Hoff DD, Rowinsky EK. A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. Clin Cancer Res 10: 1645-1656, 2004
Rothenberg ML, Liu PY, Wilczynski S, Nahhas WA, Winakur GL, Jiang CS, Moinpour CM, Lyons B, Weiss GR, Essell JH, Smith HO, Markman M, Alberts DS. Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. Gynecol Oncol 95: 506-512, 2004.
McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CPG, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23: 133-141, 2005.
Poplin EA, Benedetti JK, Estes NC, Haller DG, Mayer RJ, Goldberg RM, Weiss GR, Rivkin SE, Macdonald JS. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 23: 1819-1825, 2005.
Sarosdy M, Tangen C, Weiss G, Nestok B, Benson M, Schellhammer P, Sagalowsky A, Wood D, Jr., Crawford E. A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: A Southwest Oncology Group Study. Urol Oncol 23: 386-389, 2005.
Hernandez J, Syed S, Weiss G, Fernandes G, von Merveldt D, Troyer DA, Basler JW, Thompson IM Jr. The modulation of prostate cancer risk with alpha-tocopherol: a pilot randomized, controlled clinical trial. J Urol 174: 519-22, 2005.
Smith HO, Jiang CS, Weiss GR, Hallum AV III, Liu PY, Robinson WR, Cheng PC, Scudder SA, Markman M, Alberts DS. Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study. Int J Gynecol Cancer 16: 298-305, 2006.
Swanson GP, Faulkner J, Smalley SR, Noble MJ, Stephens RL, O'Rourke TJ, Weiss GR, Quick DP, Thompson IM Jr., Crawford ED. Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group study 9024. J Urol 176:548-53, 2006.
Davies AM, Chansky K, Lau DH, Leigh BR, Gaspar LE, Weiss GR, Wozniak AJ, Crowley JJ, Gandara DR. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
J Clin Oncol 24:5242-6, 2006.
Mita AC, Hammond LA, Bonate PL, Weiss G, McCreery H, Syed S, Garrison M, Chu QS, DeBono JS, Jones CB, Weitman S, Rowinsky EK. Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. Clin Cancer Res 12:5207-15, 2006
Mita MM, Rowinsky EK, Forero L, Eckhart SG, Izbicka E, Weiss GR, Beeram M, Mita AC, de Bono JS, Tolcher AW, Hammond LA, Simmons P, Berg K, Takimoto C, Patnaik A. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemother Pharmacol 59:165-74, 2007.
Book Chapters, Reviews:
Syed S, Weiss GR. Management of locally advanced bladder cancer: early vs. deferred chemotherapy. World J Urol 20: 175-182, 2002.
Syed S, Eng TY, Thomas CR Jr, Thompson IM, Weiss GR. Current issues in the management of advanced squamous cell carcinoma of the penis. Urol Oncol 21: 431-438, 2003.
Weiss GR. Immunotherapy of Renal Cell Carcinoma: Current and Future Strategies. Contempor Urol 17: 42-47, 2005.
Williams ME, Swerdlow SH. Correspondence re: Chibbar R et al. BCL-1 gene rearrangements in mantle cell lymphoma: A comprehensive analysis of 118 cases, including B-5-fixed tissue, by polymerase chain reaction and Southern transfer analysis. Mod Pathol 1998; 11:1089-97. [Letter]. Mod Pathol 2000.
Densmore JJ, Williams ME. Mantle cell lymphoma. Current Treatment Options in Oncology 2000; 1(3): 281-285.
Davis TA, Maloney DG, Grillo-Lopez AJ, White CA, Williams ME, Weiner GJ, Dowden S, Levy R. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with Rituximab and Interferon-alpha-2a. Clinical Cancer Res 2000; 6:2644-2652.
Kulkarni MS, Daggett JL, Bender TP, Kuehl WM, Bergsagel PL, Williams ME. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. Leukemia 2002; 16:127-134.
Ingram R, Ross M, Fintel W, Williams ME. Testicular lymphoma complicated by zoster-form cutaneous relapse. Clinical Lymphoma 2002; 2:238-241.
Tucker C, Bebb DG, Klasa RJ, Chhanabhai M, Lestou V, Horsman D, Gascoyne R, Wiestner A, Bally M, Masin D, Williams ME. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leukemia Res 2006;30:449-457; published on-line September 2005.
Densmore JJ, Williams ME. Mantle cell lymphoma. Current Treatment Options in Oncology 2003; 4:281-287.
Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, Densmore JJ, Williams ME, Taylor RP. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004; 172:3280-8.
Beum PV, Kennedy AD, Li Y, Pawluczkowycz AW, Williams ME, Taylor RP. Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab. J Immunol Methods 2004; 294:37-42.
Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA, Hamil SH, Petroni GR, Eggleton JC, Taylor RP. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced therapeutic targeting in chronic lymphocytic leukemia. J Immunol 2006; 177:7435-43.
Taylor RP, Beum PV, Li Y, Williams ME. The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006; 176:2600-9.
Li Y, Williams ME, Cousar JB, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Rituximab/CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. Submitted manuscript.
Books and Chapters:
Williams ME, Section Editor: Hematology: Medical Knowledge Self-Assessment Program 12. American College of Physicians-American Society of Internal Medicine, Philadelphia, 2001. (Includes CD Rom electronic version)
Schechter G, Broudy VC, Williams ME (editors): Hematology 2001. American Society of Hematology Education Program Book, 2001
George J, Williams ME (editors): Hematology: American Society of Hematology Self Assessment Program, 2002. Blackwell Publishing, Oxford, UK. Text and electronic versions.
Densmore JJ, Williams ME: Lymphoproliferative Diseases, ibid.
Densmore JJ, Camitta B, Williams ME. Acute lymphoblastic leukemia and lymphoblastic lymphoma. Ibid.
Williams ME, Kahn M (editors): Hematology: American Society of Hematology Self Assessment Program 2004. 2nd edition. Blackwell Publishing, Oxford, UK. Text and electronic versions.
Densmore JJ, Williams ME. Lymphoproliferative diseases, ibid.
Densmore JJ, Camitta B, Williams ME. Acute lymphoblastic leukemia and lymphoblastic lymphoma. Ibid.
Marcus R, Sweetenham J, Williams ME, eds. The Lymphomas. Cambridge University Press, Cambridge, UK. In press, 2007.
Chapter: Mantle cell lymphoma, M Dreyling, ME Williams, in press, 2007.
Greer JP, Williams ME. Non-Hodgkin Lymphoma in Adults. Wintrobe's Clinical Hematology, 12th
Edition. Lippincott Williams & Wilkins, Baltimore, MD. In press, 2007.